Introduction
Mesenchymal stem cell-mediated (MSC-mediated) regeneration therapy has been widely applied for cardiovascular disease (1) (2) (3) (4) . MSCs effect tissue repair largely via their paracrine factors and by activating endogenous progenitor cells, not only by cell replacement (1, 5, 6) . Inflammation is a normal response to pathological stress, and chronic degenerative disorders are usually associated with uncontrolled inflammation.
Unlike the well-characterized paracrine effects and differentiation potential of MSCs, the contributing mediators against inflammatory macrophages within the context of pathological progress remain to be established. We and others have shown that MSCs can modulate the macrophage phenotype; however, the underlying mechanism has remained unclear to date (7) . Macrophages are actively involved in pathological changes. In the early phase, circulating monocytes infiltrate damaged tissue and differentiate into macrophages to participate in phagocytosis with proinflammatory properties (classic M1 phenotype). M1 macrophages produce proinflammatory mediators, such as nitric oxide. In the late phase, alternatively activated M2-type macrophages induce the resolution of inflammation and tissue regeneration. When this normal process is not controlled, chronic inflammation leads to functional decline without sufficient repair. A delicate regulation of macrophage phenotype is thus functionally relevant to tissue repair, and we previously showed that chemical-induced macrophage modulation can significantly contribute to cardiac recovery after myocardial infarction (MI) (8) (9) (10) .
MSCs migrate to sites of tissue injury; however, most MSCs are cleared. Despite these limitations, MSCs continue to yield therapeutic benefits in a large number of disease models. MSCs produce and release abundant growth factors and cytokines and recently have been reported to secrete exosomes, which are rich in nucleic acids, proteins, and miRNA. Intercellular cross-talk with MSCs is highly sophisticated and involves multiple modes of communication to maintain homeostasis in the microenvironment.
Mesenchymal stem cells (MSCs) can suppress pathological inflammation. However, the mechanisms underlying the association between MSCs and inflammation remain unclear. Under coculture conditions with macrophages, MSCs highly expressed angiopoietin-like 4 (ANGPTL4) to blunt the polarization of macrophages toward the proinflammatory phenotype. ANGPTL4-deficient MSCs failed to inhibit the inflammatory macrophage phenotype. In inflammation-related animal models, the injection of coculture medium or ANGPTL4 protein increased the antiinflammatory macrophages in both peritonitis and myocardial infarction. In particular, cardiac function and pathology were markedly improved by ANGPTL4 treatment. We found that retinoic acid-related orphan receptor α (RORα) was increased by inflammatory mediators, such as IL-1β, and bound to ANGPTL4 promoter in MSCs. Collectively, RORα-mediated ANGPTL4 induction was shown to contribute to the antiinflammatory activity of MSCs against macrophages under pathological conditions. This study suggests that the capability of ANGPTL4 to induce tissue repair is a promising opportunity for safe stem cell-free regeneration therapy from a translational perspective.
In this study, we investigated whether MSC-derived mediators act during inflammation to control the progression of pathological changes. We found that MSCs highly induced angiopoietin-like 4 (ANGPTL4) to suppress activation of inflammatory macrophages. ANGPTL4 is a secreted angiopoietin-like glycoprotein and is a definite factor for commitment to antiinflammatory macrophages. ANGPTL4 is also known to play an important role in controlling innate immune responses. Given the critical role of ANGPTL4 in MSCs, we set out to study the physiological relevance of MSC-derived ANGPTL4 in mouse models of peritonitis and MI.
Results
Human MSCs inhibit inflammatory activation of macrophages via ANGPTL4. In this study, we used cells as summarized in Supplemental Figure 1 ; supplemental material available online with this article; https://doi. org/10.1172/jci.insight.125437DS1. MSCs originated from human bone marrow (hMSCs), human adipose tissue (hATSCs), or mouse bone marrow (mMSCs). Macrophage cells were derived from human monocytic THP-1 cells, human circulating CD14 + monocytes (Supplemental Figure 2) , or mouse bone marrow cells (BMDMs). Thioglycollate elicited peritoneal macrophages (pMFs) and cardiac macrophages were harvested from peritonitis and MI mouse models, respectively. Using Transwell plates for coculture, we seeded MSCs or macrophages in the lower plate for further analysis. Among the highest ranked genes, we selected Angptl4 (Supplemental Table 1 ) as a responsible factor for the antiinflammatory effect on inflammatory macrophages. We showed that ANGPTL4 mRNA and protein were consistently increased in hMSCs cocultured with LPS-stimulated human CD14 + monocyte-derived macrophages (hMFs) ( Figure 1A ). Given that ANGPTL4 is highly upregulated in MSCs when cocultured with macrophages, we sought to determine the role of ANGPTL4. We performed a successful knockdown of ANGPTL4 in hMSCs by using siRNA (Supplemental Figure 3 , A-C). After ANGPTL4 knockdown, the inhibitory activity of hMSCs on inflammatory CXCL10 in THP-1 macrophages (Supplemental Figure 3D ) and inflammatory genes (Cxcl9, Cxcl10, Cxcl11, Ccr7, Il6, and Ccl2) in hMFs ( Figure 1B ) was impaired. Because ANGPTL4 is a released protein, we sought to determine whether ANGPTL4 itself was directly associated with antiinflammatory activity of MSCs. Treatment of LPS-stimulated hMFs with recombinant ANGPTL4 protein attenuated the induction of proinflammatory genes in hMFs ( Figure 1C) .
Next, we treated human monocytic THP-1 cells with phorbol 12-myristate 13-acetate (PMA) to differentiate the cells to macrophages, and we replaced hMFs with differentiated THP-1 macrophages. Proinflammatory CXCL10 mRNA and protein were significantly reduced by coculture with hMSCs in LPS-stimulated THP-1 macrophages ( Figure 1D ). PMA-differentiated THP-1 macrophages also exhibited downregulation of inflammatory mediators by coculture with hMSCs, and we used THP-1 macrophages for mechanistic studies. To ensure that the aforementioned observations were not limited to hMSCs, we also used hATSCs and found that ANGPTL4 was highly upregulated in hATSCs cocultured with LPS-stimulated THP-1 macrophages (Supplemental Figure 3E) . These results demonstrated that MSC-released ANGPTL4 was required to exert the antiinflammatory effect. Next we examined the involvement of the NF-κB pathway by measuring the degradation of IκBα, an endogenous inhibitor of NF-κB, in macrophages. The typical degradation of IκBα followed by restoration of the protein was observed in response to LPS, whereas IκBα protein levels were not changed substantially in macrophages cocultured with hMSCs ( Figure 1E ). These results showed that hMSC coculture attenuated the proinflammatory responses via NF-κB inhibition in LPS-stimulated macrophages. Using hMFs and THP-1 macrophages, we confirmed that the inflammatory macrophages highly induced ANGPTL4 in hMSCs. Additionally, we noted that ANGPTL4 was upregulated in hMSCs by coculture with macrophages regardless of LPS stimulation (Figure 1, F-H ). LPS-induced proinflammatory genes were reduced by recombinant ANGPTL4 treatment dose dependently in THP-1 macrophages as observed in hMFs ( Figure 1I ). Thus, we used THP-1 macrophages for further studies.
ANGPTL4 is essential for an antiinflammatory effect on macrophages in MSCs. To examine the involvement of ANGPTL4 in the antiinflammatory activity of MSCs, we isolated mMSCs from ANGPTL4-knockout mice (Supplemental Figure 4) . LPS-stimulated BMDMs were cocultured with either wild-type mMSCs or knockout mMSCs for 24 hours or 48 hours, and inflammation-related genes were analyzed. Antiinflammatory activity was shown only in wild-type mMSCs and not in knockout mMSCs (Figure 2A ). In the same setting, induction of proinflammatory iNOS protein was prominently blocked, and antiinflammatory Arg1 protein was significantly upregulated in LPS-stimulated BMDMs by coculture with wild-type mMSCs but not with knockout mMSCs ( Figure 2B ). These results suggested that ANGPTL4 in MSCs is critical for exerting the antiinflammatory effect against macrophages.
Next, we sought to determine how hMSCs acted on macrophages to exert their antiinflammatory activity. First, to determine the hMSC-released exosomes, we pretreated the hMSCs with GW4869, a well-known inhibitor of exosome release, to block exosome production, but found no differences in the inhibition of proinflammatory CXCL10 mRNA in THP-1 macrophages ( Figure 3A) . Then, we pretreated macrophages with cytochalasin D, which is known to inhibit exosome uptake, before coculture with hMSCs, and found no difference in CXCL10 inhibition in macrophages regardless of cytochalasin D pretreatment ( Figure 3B ). Second, because ANGPTL4 has been reported to bind integrin β 1 or integrin α v β 3 (5, 11), we neutralized these binding sites on macrophages by antibodies before coculture. Blockade of integrin β 1 and integrin α v β 3 impaired the inhibition of CXCL10 in THP-1 macrophages by hMSCs ( Figure 3C ). These results indicated that ANGPTL4 released from MSCs may act on macrophages through integrin subtypes rather than exosomes.
ANGPTL4 governs the profile of inflammatory-soluble mediators in MSCs.
Further analysis of the released and intracellular proteins associated with MSCs was performed by antibody array. After coculture with LPS-stimulated THP-1 macrophages, hMSC coculture medium (CCM) and hMSC lysate were collected from both control siRNA-transfected ( Figure 4A ) and ANGPTL4 siRNA-transfected hMSCs (Figure 4B ). CXCL11 and CSF2 were reduced, whereas IL-8 was increased in CCM from ANGPTL4-knockdown hMSCs. In addition, CSF2 and IL-1β were reduced, whereas MIP-1α and MIP-1β were increased, in ANGPTL4-knockdown hMSCs. To further support these results, we performed real-time PCR, and these factors were shown to change consistently with the antibody array ( Figure 4C ).
ANGPTL4 in MSCs supports the antiinflammatory effect in a mouse peritonitis model. To functionally show the critical role of ANGPTL4 in MSCs to inhibit pathological inflammation, we collected CCM from wild-type or ANGPTL4-knockout mMSCs cocultured with BMDMs. We induced peritonitis in mice with thioglycollate injection. On day 3, CCM was injected into the peritoneum, and 20 hours later, mice were stimulated by intraperitoneal injection with LPS for 4 hours ( Figure 5A ). Intriguingly, circulating ANGPTL4 was substantially increased, while IL-6 was reduced in the wild-type mMSC-CCM group but not in the knockout mMSC-CCM group ( Figure 5B ). On the other hand, levels of ANGPTL4 and IL-6 were not different in peritoneal lavage in all groups ( Figure 5C ). We next analyzed inflammation-related mediators of peritoneal macrophages. In a series of real-time PCR experiments, the peritoneal macrophages isolated from the wild-type mMSC-CCM group showed higher expression of antiinflammatory Arg1, CD206, and IL-10 and lower levels of proinflammatory iNOS, IL-6, IL-1β, and CD80 compared with the knockout mMSC-CCM group ( Figure 5D ).
Additionally, we supported the essential role of ANGPTL4 in antiinflammatory activity of MSCs by using CCM collected from hMSCs with ANGPTL4 knockdown and THP-1 macrophages. The inhibitory effect of hMSC(siANGPTL4)-CCM on the induction of CXCL10 and CXCL11 was not observed in LPS-stimulated THP-1 macrophages (Supplemental Figure 5A) . In a peritonitis mouse model, circulating ANGPTL4 was increased, while IL-6 was reduced in the hMSC(siCon)-CCM group but not in the hMSC(siANGPTL4)-CCM group. However, peritoneal lavage did not show any differences in the levels of ANGPTL4 and IL-6 in either group (Supplemental Figure 5B ). The antiinflammatory protein CD206 and antiinflammatory genes (Arg1, Cd206, and Il10) were highly expressed in the peritoneal macrophages isolated from the hMSC(siCon)-CCM group compared with the hMSC(siANGPTL4)-CCM group (Supplemental Figure 5C ). The representative antiinflammatory marker CD206 was upregulated in the peritoneal macrophages isolated from the hMSC(siCon)-CCM group but not in the hMSC(-siANGPTL4)-CCM group (Supplemental Figure 5D ). Inflammation-related cytokines were quantified in mouse plasma by using multiplex ELISA. IL-1α and IL-6 were lower in the hMSC(siCon)-CCM group than in the MSC(siANGPTL4)-CCM group (Supplemental Figure 5E) .
ANGPTL4 supports the antiinflammatory effect in a mouse peritonitis model. To confirm that ANGPTL4 was responsible for the antiinflammatory activity of MSC CCM, we injected Veh or recombinant ANGPTL4 protein (50 ng or 200 ng) into mice with peritonitis ( Figure 6A ). Plasma IL-6 was reduced in both the 50-ng ANGPTL4 group and the 200-ng ANGPTL4 group, whereas circulating ANGPTL4 did not differ (Figure 6B) . A series of real-time PCRs of peritoneal macrophages showed that the 200-ng ANGPTL4 group had significantly increased expression of the antiinflammatory Arg1, CD206, and IL-10 and decreased proinflammatory iNOS, IL-6, and IL-1β. On the other hand, 50-ng ANGPTL4 treatment showed a partial were isolated from wild-type and ANGPTL4-knockout mice. In coculture settings, inflammation-related markers were assessed in LPS-stimulated mouse bone marrow-derived macrophages (BMDMs) with or without coculture with mMSCs at 24 hours and 48 hours. Wild-type mMSCs significantly suppressed proinflammatory markers, while knockout mMSCs did not. Antiinflammatory markers in macrophages were remarkably induced only by wild-type mMSCs but not by knockout mMSCs. n = 4. (B) In the same setting as A, protein levels of iNOS and Arg1 were measured by Western blot. Intensity quantification is representative of mean ± SEM. n = 3. Data are represented as mean ± SEM. inhibitory effect on inflammation ( Figure 6C ). In plasma cytokine analyses, significant reductions of IL-6, IL-1α, IL-1β, and IL-10 upregulation were observed only in the 200-ng ANGPTL4 group and not in the 50-ng ANGPTL4 group ( Figure 6D ). CD206-expressing peritoneal macrophages were more abundant in the group treated with 200 ng ANGPTL4 than in the Veh-treated group ( Figure 6E ). In addition to peritoneal macrophages, we assessed the antiinflammatory effect of 200-ng ANGPTL4 treatment in BMDMs isolated from mice with peritonitis. As in the peritoneal macrophages, antiinflammatory genes were increased, whereas proinflammatory markers were downregulated in the LPS-stimulated BMDMs from the ANGPTL4 group ( Figure 6F ). From these results, we suggest that treatment with 200 ng ANGPTL4 protein was comparable to MSC CCM in terms of antiinflammatory activity.
ANGPTL4 in MSCs eases cardiac inflammation and improves cardiac function.
In the peritonitis model, we noticed that ANGPTL4 treatment exerted its antiinflammatory effect against pathologically activated macrophages. Next, to address the relevance of our observations for advanced cardiac inflammation, we used an MI model as summarized in Figure 7A . CCM was injected into the mouse intraperitoneally, followed by MI induction. At 2 days, plasma and heart tissues were collected. Inflammatory IL-6 and IL-1β in the plasma were reduced by the injection of wild-type mMSC CCM but not by knockout mMSC CCM ( Figure  7B ). In heart tissues, antiinflammatory Arg1, CD206, and IL-10 were increased, while proinflammatory iNOS, IL-6, IL-1β, and MCP-1 were reduced in the wild-type mMSC-CCM group but not in the knockout mMSC-CCM group ( Figure 7C) . In Western blots, the antiinflammatory markers Arg1 and CD206 were not upregulated, and the proinflammatory markers iNOS and MCP-1 were not downregulated in the knockout mMSC-CCM group ( Figure 7D ). To lend further support to these findings, hMSC(siANGPTL4) CCM was applied to the MI model (Supplemental Figure 6A) . In the hMSC(siANGPTL4)-CCM group, no antiinflammatory effects of CCM were shown in the circulating levels of IL-6 and IL-1β or the expression patterns of antiinflammatory markers and proinflammatory markers (Supplemental Figure 6, B-D) . 
ANGPTL4 eases cardiac inflammation and improves cardiac function.
To evaluate the functional role of ANGPTL4 in MI, ANGPTL4 protein was injected every other day into MI mice. At 2 days, plasma and heart tissues were collected ( Figure 8A ). In heart tissues, antiinflammatory markers were increased, while proinflammatory markers were reduced, in the ANGPTL4 group (Figure 8, B and C) . Circulating IL-6 and IL-1β were reduced by the injection of ANGPTL4 ( Figure 8D ). To further analyze the effect of ANGPTL4 on the phenotype of cardiac macrophages, mice were subjected to MI for 3 days or 2 weeks ( Figure 8E ). At day 3 after MI, inflammatory cardiac macrophages, which were identified by sorting with CD45 hi CD11b
hi cells more abundant in the Veh group than in the ANGPTL4 group ( Figure 8F ). Moreover, mRNA levels of antiinflammatory Arg1 and Cd206 were higher in the cardiac macrophages isolated from the MI mice injected with ANGPTL4 protein ( Figure 8G ). These results led us to analyze the therapeutic effect of ANGPTL4 protein in the post-MI condition. At 2 weeks after MI, heart tissues were collected, and cardiac function was assessed by echocardiography and immunohistochemistry ( Figure 8H ). The gross sections of the heart tissues showed better preserved cardiac structure in the group treated with ANGPTL4 than in the Veh-treated group (Supplemental Figure 7A) , and cardiac fibrosis was attenuated in the group treated with ANGPTL4 (Supplemental Figure 7B) . To compare macrophage infiltration, CD68 + macrophages were visualized. We found that the distribution of macrophages was smaller in the group treated with ANGPTL4 (Supplemental Figure 7C) . The distribution of the antiinflammatory marker CD206 was higher in the group treated with 200 ng ANGPTL4 than in the Veh group (Supplemental Figure 7D) . Additionally, when we assessed the distribution of vWF + cells, we found that angiogenesis in the infarcted zone was better in the group treated with ANGPTL4 than in the Veh-treated group (Supplemental Figure 7E) .
To determine the relevance of ANGPTL4 to cardiac pathology, we measured cardiac function. Echocardiographic indexes indicated that cardiac remodeling and function were improved in the group treated with 200 ng ANGPTL4 compared with Veh ( Figure 8I ). Next, we analyzed the phenotype of cardiac macrophages by double staining with CD68 and CD206 and found that CD206-expressing macrophages were more abundant in the ANGPTL4 group than in the Veh group ( Figure 8J) .
To further support the cardioprotective effect of ANGPTL4, we examined the effect of ANGPTL4 on cardiomyocytes and cardiac fibroblasts in addition to macrophages. Neonatal cardiomyocytes and cardiac fibroblasts were stimulated with angiotensin II (Ang II), a major mediator of cardiac damage (12) . In cardiomyocytes, Ang II-induced upregulation of apoptotic protein BAX was significantly suppressed, while antiapoptotic BCL2 was highly induced by ANGPTL4 treatment (Supplemental Figure 7F) . Then the effect of ANGPTL4 on Ang IIinduced profibrotic mediators was assessed. Connective tissue growth factor (CTGF) was substantially inhibited in cardiomyocytes (Supplemental Figure 7G) , and collagen (Col1a1) and CTGF in cardiac fibroblasts were also remarkably inhibited by ANGPTL4 treatment (Supplemental Figure 7H) . Thus, in the infarcted heart, ANGPTL4 may exert its therapeutic effect on macrophages, cardiomyocytes, and cardiac fibroblasts.
Identification of retinoic acid receptor-related orphan receptor α as a transcriptional inducer of ANGPTL4.
Next, we explored transcription factor binding sites of the ANGPTL4 promoter to address how ANGPTL4 is induced in MSCs and found that retinoic acid receptor-related orphan receptor α (RORα) was a candidate transcription factor with a binding site on the ANGPTL4 promoter. RORα was induced when hMSCs were cocultured with THP-1 macrophages (Supplemental Table 1 and Figure 9A ). To examine whether RORα is required for ANGPTL4 transcriptional activity, we knocked down RORα and found that ANGPTL4 upregulation was blunted in hMSCs with RORα knockdown transcriptionally and translationally ( Figure 9 , B and C). Alternatively, RORα-overexpressed hMSCs showed significant upregulation of ANGPTL4 (Supplemental Figure 8A ). Besides, hMSCs with RORα knockdown failed to suppress CXCL10 and CXCL11 in LPS-stimulated macrophages ( Figure 9D) . Then, to study whether inflammatory cytokines released from infiltrated macrophages may induce ANGPTL4 in MSCs (13, 14) , we treated hMSCs with IL-1β or TNF-α. Both RORα and ANGPTL4 were upregulated in hMSCs treated with IL-1β or TNF-α ( Figure 9E ), and these results suggested that inflammatory mediators derived from macrophages contributed to ANGPTL4 upregulation through RORα induction in MSCs. Induction of RORα and ANGPTL4 by treatment with IL-1β or TNF-α was blunted in hMSCs with RORα knockdown (Figure 9F ) Peritonitis was induced by thioglycollate injection for 3 days. CCM collected from wild-type mMSCs or knockout mMSCs was injected into the peritoneum followed by LPS stimulation for 4 hours. Peritoneal macrophages were isolated for further analyses. Circulating ANGPTL4 and IL-6 in plasma (B) and peritoneal lavage (C) were quantified. (D) Inflammation-related genes were assessed in peritoneal macrophages collected from mice with peritonitis (n = 8). Mice were injected with vehicle (Veh) or CCM i.p. on days 0 and 2. n = 5 for circulating ANGPTL4; n = 7 for circulating IL-6; n = 6 for ANGPTL4 and IL-6 in peritoneal lavage. Data are represented as mean ± SEM.
# P < 0.05; ## P < 0.01; ### P < 0.001 (by Student's t test or 1-way ANOVA with Bonferroni's multiple-comparisons test). Furthermore, pretreatment of hMSCs with SR1001, an inverse agonist of RORα and RORγ, or SR3335, a selective inverse agonist of RORα, failed to upregulate ANGPTL4 as well as RORα in the coculture with THP-1 macrophages ( Figure 9G ). Besides, SR1078, an agonist of RORα, substantially increased Rora mRNA in hMSCs along with ANGPTL4 induction (Supplemental Figure 8B) . This result showed the association of RORα and ANGPTL4 in hMSCs in response to inflammatory macrophages. We then evaluated the binding of RORα on the ANGPTL4 promoter by ChIP assay. Chromatin fragments were immunoprecipitated with a nonspecific IgG as a negative control or with a specific anti-RORα antibody, and real-time PCR analysis of immunoprecipitated chromatin showed that RORα bound to the ANGPTL4 promoter ( Figure 9H ). To find the critical regions in the ANGPTL4 promoter, we established ANGPTL4 promoter-LUC reporter plasmids: full-length promoter and a series of deleted promoters. Deletion mutants were transfected into HEK293T cells, which were stimulated with hMSC CCM. Interestingly, the promoter activity of cells transfected with pGL3-1700 promoter was apparently reduced (about 50%-60% reduction) compared with that of cells transfected with Figure 7 . Cardiac inflammation is attenuated by coculture medium in a mouse myocardial infarction model. (A) MI was induced by coronary artery ligation, then CCM from wild-type mouse mMSCs or ANGPTL4-knockout mMSCs was injected i.p. Heart tissues and blood were collected after 2 days for further studies. (B) Circulating IL-6 and IL-1β were not reduced in mice injected with knockout mMSC CCM. n = 5 for each group. The expression levels of inflammatory markers in the heart tissue were assessed by real-time PCR (C, n = 4) and Western blot (D, n = 3). Antiinflammatory activity was not observed in the knockout mMSC-CCM group. Data are represented as mean ± SEM.
# P < 0.05; ## P < 0.01; ### P < 0.001 (by Student's t test or 1-way ANOVA with Bonferroni's multiple-comparisons test).
the full promoter construct, and pGL3-1100 promoter lost its activity. These results suggested that the region from -1700 to -2300 is possibly involved in the activation of the ANGPTL4 promoter by inflammatory macrophages ( Figure 9I ). For confirmatory experiments, we pretreated hMSCs with SR1001 before coculture with THP-1 macrophages and found that SR1001 effectively abolished the inhibition of CXCL10 and CXCL11 induction (Supplemental Figure 8C ).
Discussion
After MSC administration, migration and engraftment of the stem cells in the lesion induce transdifferentiation into functional cells, angiogenesis, wound healing, and the resolution of inflammation. MSCs exhibit remarkable immunosuppressive activities in various diseases (15, 16) besides the direct incorporation of MSCs in tissue regeneration, although the mechanisms of these actions remain unresolved.
A number of studies have demonstrated that the therapeutic effects of MSCs are associated with soluble paracrine factors (6, 17, 18) . The antiinflammatory potential of MSCs cannot be pinned to a single factor or mechanism, but rather to soluble factors, many of which are involved in inflammatory environments (18) . Macrophages are one of the multiple factors contributing to the pathological progress of cardiovascular disease in terms of stem cell-induced cardiac regeneration and reparative roles of inflammatory responses (19, 20) .
Critically, the present study identified ANGPTL4 as having an intricate interplay with MSCs against inflammatory macrophages. A screen for molecules whose deficiency blocked the modulatory activity of MSCs against stimulated macrophages pointed to ANGPTL4 as a critical regulator of MSCs, and these in vitro observations were corroborated by in vivo studies in mouse models of peritonitis and MI.
ANGPTL4 belongs to the angiopoietin-like protein (ANGPTL) family, which is structurally similar to the angiopoietins and does not bind to the receptors classically targeted by angiopoietins. The ANGPTL family generally is considered orphan ligands (21, 22) . Circulating ANGPTL4 is cleaved into an N-terminal fragment and a C-terminal fragment, and mutating the ANGPTL4 cleavage region improves the stability of the full-length protein (23) . ANGPTL4 is a paracrine and endocrine regulator of lipid metabolism and is ubiquitously expressed in humans, mainly in the liver, adipose tissue, blood plasma, placenta, small intestine, and heart (24). In MSCs, ANGPTL4 is upregulated to induce MMP-13 during chondrogenic differentiation (25) . There have been conflicting reports concerning the role of ANGPTL4 in atherosclerosis. For example, in one study, ANGPTL4 overexpression suppressed lipid overloading in macrophages and reduced atherosclerotic plaque development without hypertriglyceridemia (26) . In another study, ANGPTL4-deficient mice had a better lipid profile and smaller atherosclerotic lesions than mice without this deficiency, whereas macrophage-specific deficiency of ANGPTL4 accelerated atherosclerosis progression via vascular inflammation (27) . A recent study showed that genetic ablation of ANGPTL4 in adipose tissue resulted in enhanced lipoprotein lipase activity and reduced atherosclerosis (28) . These discrepancies can be partially explained by the finding that germline deletion of ANGPTL4 results in severe peritonitis, severe gut inflammation, and decreased survival with a marked reduction in atherosclerosis. Lipoprotein lipase is the primary enzyme that hydrolyzes lipoprotein triglycerides, and ANGPTL4 is the endogenous inhibitor of lipoprotein lipase. A population-based study revealed that low plasma triglyceride levels were significantly related with loss-offunction alleles in ANGPTL4, which is unable to inhibit lipoprotein lipase activity in vitro (29) . In nephrotic syndrome, elevated circulating ANGPTL4 protein in podocytes exerts a systemic feedback response against proteinuria and results in hypertriglyceridemia (30) . In other studies, carriers of both inactivating mutations in ANGPTL4 and loss-of-function mutations in ANGPTL4 had lower levels of triglycerides, and these mutations were associated with a lower risk of coronary artery disease than in noncarriers (31, 32) . In a mouse MI model, ANGPTL4 preserved the microcirculatory network and improved endothelial barrier function by restoring vascular integrity during ischemia/reperfusion injury (33) . In MI patients, circulating ANGPTL4 levels predict no-reflow after successful percutaneous intervention (34) .
ANGPTL4 has multifaceted functions and its physiological roles may be largely dependent on the pathological conditions. In this study, we highlighted that ANGPTL4 was highly induced and released from MSCs in response to inflammatory macrophages. To decipher the role and mechanism of action of ANGPTL4 in MSCs, we first compared the inhibitory effects of naive MSCs and ANGPTL4-deficient MSCs. ANGPTL4 was markedly induced in MSCs in response to coculture with either unstimulated macrophages or LPS-stimulated macrophages (Supplemental Table 1 ; Figure 1 , F-H; and Supplemental Figure  3 , B and C). Recombinant ANGPTL4 protein itself substantially inhibited the induction of proinflammatory genes in LPS-stimulated macrophages ( Figure 1I ), and this finding suggested that ANGPTL4 was specifically induced in MSCs in the inflammatory environment.
Given that ANGPTL4 is substantially induced in MSCs by interaction with macrophages, next we tried to identify an intrinsic inducer of ANGPTL4. Numerous binding sites have been found within the ANGPTL4 promoter, and we selected RORα as a candidate transcription factor. RORα is one of the unclear receptors and has been cloned by virtue of its strong homology with the retinoic acid receptor. RORα binds DNA as a monomer to specific sites called RORα response elements, which consist of a 6-bp AT-rich sequence preceding the half-core PuGGTCA motif (35) . RORα is a lipid-sensing nuclear receptor with diverse biological functions, including regulation of lipid metabolism and inflammation, and was reported to exert an antiinflammatory role by inhibiting NF-κB p65 translocation (36) . We found ROR bound on the ANGPTL4 promoter in MSCs by coculture with macrophages. Genetic and pharmacological disruption of RORα in MSCs failed to induce ANGPTL4 and inhibited CXCL10 and CXCL11 induction in cocultured macrophages. These results suggested that the RORα-ANGPTL4 axis was an essential component for the immunomodulatory activity of MSCs.
To examine whether administration of CCM to a pathological macrophage-rich environment can ease inflammation, peritonitis and MI were induced in mice. As anticipated, the expression of antiinflammatory phenotype markers in peritoneal macrophages was higher in mice injected with MSC CCM and lower in mice injected with ANGPTL4-knockdown MSC CCM. This in vivo finding was consistent with the in vitro data. More interestingly, application of recombinant ANGPTL4 protein was comparable to MSC CCM in terms of the remarkable suppression of inflammatory macrophages and circulating inflammatory cytokine levels. In addition to peritonitis, we studied the effects of MSC CCM and ANGPTL4 protein in the MI model. The Veh group showed a significant induction of iNOS, whereas no detectable Arg1 was found in the infarcted heart tissue. On the other hand, Arg1 was remarkably increased in the MSC(siCon)-CCM group compared with the MSC(siANGPTL4)-CCM group. Next, we decided to take inspiration from multifunctional stem cells and the ways in which they induce tissue repair and modulate pathological immune cells in inflammatory lesions. Interestingly, proinflammatory mediators were significantly suppressed, and antiinflammatory mediators were upregulated in the infarcted heart tissue by application with recombinant ANGPTL4 protein. The most impressive impact of ANGPTL4 application was the meaningful structural and functional recoveries after MI. The results of this study support the view that a specific pattern of interaction of MSCs with macrophages exists within the disease niche and most likely contributes to the progressive cardiac regeneration and reduction in fibrosis. No previous reports to our knowledge have dealt with the specific role of ANGPTL4 in MSCs from a therapeutic perspective, and our results demonstrate that ANGPTL4 delivery is efficacious both for easing inflammation as well as for inducing tissue regeneration.
Transplantation of MSCs has several potential disadvantages. The engraftment rate is low, DNA can be damaged during in vitro expansion, and the therapeutic effect is dependent on cell dose, delivery route, and timing. Several reports have shown that some patients who receive adult stem cell therapy occasionally have unexpected adverse outcomes, such as brain tumor (37) , angiomyeloproliferative lesions (38) , and glioproliferative lesions (39) . A recent study identified missense mutations in TP53, a tumor suppressor, in both human embryonic stem cells and human induced pluripotent stem cells, and suggested the need for regular genetic testing of stem cells for further clinical applications (40) . Current issues concerning stem cell therapy that should be aggressively considered include the lack of long-term follow-up of the cell fate of transplanted stem cells, possible involvement in tumor formation, and undisclosed mutations (38) (39) (40) (41) . Translation of basic research to clinical trials can hardly succeed because of these issues, and thus the use of an MSC-derived soluble factor, such as ANGPTL4, could be a better and safer opportunity for cell-free regeneration therapy. Instead of intensive concentration on developing techniques to increase the therapeutic efficacy of stem cells, replacing stem cells with an apparent effector molecule would be a better choice for safe and effective therapy.
Here we have demonstrated the potentially novel antiinflammatory role of ANGPTL4 secreted from MSCs in a pathological microenvironment, and we define a molecular mechanism by which RORα/ANGPTL4 regulates inflammation-related gene expression in macrophages (Supplemental Figure 9 ). Our further work will specifically address the role of ANGPTL4 following MI in ANGPTL4-deficient mice.
